Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results
Rhea-AI Summary
Neurocrine Biosciences (Nasdaq: NBIX) has announced its schedule for the third quarter 2024 financial results conference call and webcast. The event is set for October 30, 2024, with the press release at 4:00 a.m. PT and the conference call at 5:00 a.m. PT. Investors can access the webcast on the company's website, with a replay available for approximately one month.
Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company dedicated to developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. The company's portfolio includes FDA-approved treatments for tardive dyskinesia, Huntington's disease-associated chorea, endometriosis, and uterine fibroids. They also have multiple compounds in mid- to late-phase clinical development across their core therapeutic areas.
Positive
- Neurocrine Biosciences has FDA-approved treatments in its portfolio
- The company has a robust pipeline with multiple compounds in mid- to late-phase clinical development
Negative
- None.
News Market Reaction
On the day this news was published, NBIX gained 0.71%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Conference Call and Webcast Scheduled for Wednesday, October 30
The schedule for the press release and conference call / webcast is as follows:
• Q3 2024 Press Release: | October 30, 2024 at 4:00 a.m. PT / 7:00 a.m. ET |
• Q3 2024 Conference Call: | October 30, 2024 at 5:00 a.m. PT / 8:00 a.m. ET |
• Domestic Dial-In Number: | 800-225-9448 |
• International Dial-In Number: | 203-518-9708 |
• Conference ID: | NBIX |
The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X (Formerly Twitter) and Facebook. (*in collaboration with AbbVie)
NEUROCRINE BIOSCIENCES, NEUROCRINE, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. The Neurocrine logo is a trademark of Neurocrine Biosciences, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-third-quarter-2024-financial-results-302271930.html
SOURCE Neurocrine Biosciences, Inc.
FAQ
When will Neurocrine Biosciences (NBIX) release its Q3 2024 financial results?
What time is the Neurocrine Biosciences (NBIX) Q3 2024 earnings conference call?
How can investors access Neurocrine Biosciences' (NBIX) Q3 2024 earnings webcast?
What are the main therapeutic areas Neurocrine Biosciences (NBIX) focuses on?
